Friday, 8 August 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 08 August 2025
News

Seven drugs join TGA review list

Posted 7 August 2025 AM

The TGA accepted seven innovative medicines for review in June, including Novartis’ long-lost lung cancer treatment Tabrecta initially filed three years ago.

Tabrecta was filed with the TGA under orphan status in June 2022 for the treatment of non-small cell lung cancer with genetic MET alterations but never made it over the line, disappearing from the regulator’s review list in the following year.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (15)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Devices (1)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.